Drugs / TAK-071
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02918266 | Nov 2016 → Aug 2017 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02769065 | May 2016 → Jun 2017 | Alzheimer disease | Takeda | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04334317 | Oct 2020 → Feb 2023 | Parkinson disease | Takeda | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-071 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02918266 ↗ |
| Action | Activate | “a novel muscarinic acetylcholine receptor 1 positive allosteric modulator” NCT02918266 ↗1“Muscarinic acetylcholine receptor M1 positive allosteric modulator” CHEMBL4594351 ↗ |
| Modality | Small molecule | — CHEMBL4594351 ↗ |
| Route | Oral | “TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.” NCT02769065 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 positive allosteric modulator” CHEMBL4594351 ↗ |